In the last decade, ECU, a monoclonal antibody against C5 complement fraction, has revolutionized PNH natural history, reducing the incidence of anemia, transfusion dependency, and thrombosis, and thus increasing patients’ quality of life. This evidence concerns the gene C5 and anemia.